rs11615
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In addition, no evidence of association was observed between prognosis in osteosarcoma and <i>ERCC1</i> rs11615, <i>ERCC1</i> rs3212986, <i>ERCC1</i> rs2298881, <i>ERCC2</i> rs13181, <i>ERCC4</i> rs1800067, and <i>ERCC5</i> rs1047768 polymorphisms.
|
29950854 |
2018 |
rs11615
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The ERCC2-rs1799793 AA+AC > CC (OR=1.3428, 95% CI=1.0201; 1.7674) had an effect on the risk of osteosarcoma development, whereas, there were no significant associations among the other ERCC SNPs (ERCC1 rs3212986, ERCC1 rs11615, and ERCC2 rs13181) and osteosarcoma.
|
30402838 |
2018 |
rs11615
|
|
|
0.100 |
GeneticVariation |
BEFREE |
ERCC1 (C118T (rs11615) and C8092A (rs3212986)) and ERCC2 (A751C (rs171140) and G312A (rs1799793)) polymorphisms were analysed in 44 patients with osteosarcoma, who were treated with cisplatin based neoadjuvant chemotherapy.
|
29980176 |
2018 |
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The ERCC2 rs1799793 polymorphism is related to the high risk of osteosarcoma development.
|
30402838 |
2018 |
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This study did not support rs11615, rs13181 or rs1799793 to be used as surrogate markers for clinical outcome of osteosarcoma with chemotherapy.
|
30544402 |
2018 |
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
ERCC1 (C118T (rs11615) and C8092A (rs3212986)) and ERCC2 (A751C (rs171140) and G312A (rs1799793)) polymorphisms were analysed in 44 patients with osteosarcoma, who were treated with cisplatin based neoadjuvant chemotherapy.
|
29980176 |
2018 |
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In the present meta-analysis, we demonstrated that the homozygous variant genotypes in <i>ERCC2</i> rs1799793 and <i>ERCC5</i> rs2296147 were significantly associated with OS in osteosarcoma (TT vs GG for rs1799793: HR = 0.62, 95% CI = 0.41-0.93, <i>P</i><sub>heterogeneity</sub> = 0.310, <i>I</i><sup>2</sup> = 15.3%, <i>P</i> = 0.020; TT vs CC for rs2296147: HR = 0.42, 95% CI = 0.23-0.78, <i>P</i><sub>heterogeneity</sub> = 0.708, <i>I</i><sup>2</sup> = 0.0%, <i>P</i> = 0.006).
|
29950854 |
2018 |
rs11615
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This suggests rs11615 may be a useful genetic marker for predicting osteosarcoma prognosis.
|
28977987 |
2017 |
rs11615
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Haplotype containing the rs1799793-T and rs11615-T alleles was associated with a statistically increased osteosarcoma risk, OR (95% CI) = 1.47 (1.12-1.92).
|
28474168 |
2017 |
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Participants rs1799793-GT or -TT and rs4150441-GA or -AA genotype have the highest osteosarcoma risk, compared to subjects with rs1799793-GG and rs4150441-GG genotype, OR (95% CI) = 2.87 (1.21-4.63), after covariates adjustment.
|
28474168 |
2017 |
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our meta-analysis included eleven studies in which four SNPs (ERCC1 rs11615 and rs3212986, ERCC2 rs13181 and rs1799793) reportedly associated with osteosarcoma prognosis were investigated.
|
28977987 |
2017 |
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Multivariate logistic regression analysis did not reveal significant associations between ERCC2 rs13181/rs1799793 or ERCC3 rs4150441/ rs4150506 gene polymorphisms and the development of osteosarcoma in codominant, dominant, and recessive models.
|
27051024 |
2016 |
rs11615
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In summary, our results suggested that the ERCC1 rs11615 and rs2298881 polymorphisms play important roles in the response to chemotherapy mediated by the DNA repair pathway and in the clinical outcome of osteosarcoma.
|
26345951 |
2015 |
rs11615
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, our findings suggest that ERCC1 rs11615 and ERCC1 rs2298881 genetic polymorphisms are significantly associated with poor response to chemotherapy and unfavourable survival of osteosarcoma.
|
26339355 |
2015 |
rs11615
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, our results suggest that ERCC1 rs11615 and ERCC2 rs1799793 may be useful genetic prognostic markers for osteosarcoma in a Chinese population.
|
26436406 |
2015 |
rs11615
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In the Cox proportional hazards model, after adjusting for potential confounding factors, we found that individuals carrying CC genotype of ERCC1 rs11615 was associated with decreased risk of death from osteosarcoma, and the HR (95% CI) was 0.43 (0.15-0.93).
|
25755792 |
2015 |
rs11615
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, our results suggest that the ERCC1 rs11615 polymorphism might influence the response to cisplatin-based chemotherapy and affect the clinical outcome for osteosarcoma patients.
|
26400354 |
2015 |
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, our results suggest that ERCC1 rs11615 and ERCC2 rs1799793 may be useful genetic prognostic markers for osteosarcoma in a Chinese population.
|
26436406 |
2015 |
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, our study found that the ERCC2 Asn312Asp gene polymorphism likely plays an important role in influencing the chemotherapy response and overall survival of patients with osteosarcoma.
|
26505449 |
2015 |
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In addition, there is no evidence of association on ERCC1 Asn118Asn, ERCC1 Gln504Lys, and ERCC2 Asp312Asn polymorphisms with prognosis in osteosarcoma.
|
25023406 |
2014 |
rs11615
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Excision repair cross-complementing (ERCC) group 2 (XPD; rs13181 and rs1799793), group 5 (XPG; rs17655) and group 1 (XPA; rs3212986 and rs11615) polymorphisms were analyzed in a group of 130 homogenously treated patients with high-grade osteosarcoma, for association with event-free survival (EFS), using the Kaplan-Meier plots and log-rank test.
|
21826087 |
2012 |
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We first report associations of four SNPs, ERCC1 Asn118Asn, ERCC1 Gln504Lys, ERCC2 Asp312Asn and ERCC2 Lys751Gln, with risk of death from osteosarcoma in a Chinese population, indicating ERCC1 118T/T and ERCC2 A/A may be used as surrogate markers for clinical outcome of osteosarcoma treatment with cisplatin.
|
23098477 |
2012 |
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This study suggests that XPD rs1799793 could be a marker of os</span>teosarcoma associated with features conferring either a better prognosis or a better outcome after platinum therapy, or both.
|
21826087 |
2012 |
rs13181
|
|
|
0.080 |
GeneticVariation |
BEFREE |
The ERCC2-rs1799793 AA+AC > CC (OR=1.3428, 95% CI=1.0201; 1.7674) had an effect on the risk of osteosarcoma development, whereas, there were no significant associations among the other ERCC SNPs (ERCC1 rs3212986, ERCC1 rs11615, and ERCC2 rs13181) and osteosarcoma.
|
30402838 |
2018 |
rs13181
|
|
|
0.080 |
GeneticVariation |
BEFREE |
This study did not support rs11615, rs13181 or rs1799793 to be used as surrogate markers for clinical outcome of osteosarcoma with chemotherapy.
|
30544402 |
2018 |